Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Proton Rahman

Showing results (221-230 of 260) with videos related to

Pageof 26
Sort By:
Frontiers in Genetics|April 30, 2019
Integrative Approach to Reveal Cell Type Specificity and Gene Candidates for Psoriatic Arthritis Outside the MHCMatthew T Patrick, Philip E Stuart, Kalpana Raja, et al.
Rheumatology (Oxford, England)|April 6, 2021
Resolution of enthesitis by guselkumab and relationships to disease burden: 1-year results of two phase 3 psoriatic arthritis studiesDennis McGonagle, Iain B McInnes, Atul Deodhar, et al.
Arthritis & Rheumatology (Hoboken, N.J.)|October 12, 2020
Efficacy and Safety of Guselkumab, an Interleukin-23p19-Specific Monoclonal Antibody, Through One Year in Biologic-Naive Patients With Psoriatic ArthritisIain B McInnes, Proton Rahman, Alice B Gottlieb, et al.
Arthritis & Rheumatology (Hoboken, N.J.)|January 22, 2024
Modulation of Interleukin-23 Signaling With Guselkumab in Biologic-Naive Patients Versus Tumor Necrosis Factor Inhibitor-Inadequate Responders With Active Psoriatic ArthritisStefan Siebert, Laura C Coates, Georg Schett, et al.
The Journal of Rheumatology|February 15, 2024
Residual Disease Activity in Canadian Patients With Psoriatic Arthritis Treated With Advanced Therapies: Results From a Multiregistry Analysis (UNISON-PsA)Dafna D Gladman, Vinod Chandran, Cheryl F Rosen, et al.
The Journal of Rheumatology|May 2, 2021
Pooled Safety Results Through 1 Year of 2 Phase III Trials of Guselkumab in Patients With Psoriatic ArthritisProton Rahman, Christopher T Ritchlin, Philip S Helliwell, et al.
The Journal of Rheumatology|September 28, 2007
The Canadian Rheumatology Association/ Spondyloarthritis Research Consortium of Canada treatment recommendations for the management of spondyloarthritis: a national multidisciplinary stakeholder projectWalter P Maksymowych, Dafna Gladman, Proton Rahman, et al.
European Journal of Human Genetics : EJHG|September 4, 2014
Fine mapping of eight psoriasis susceptibility lociSayantan Das, Philip E Stuart, Jun Ding, et al.
The Journal of Rheumatology|July 1, 2025
Residual Disease Activity and Burden of Disease in Canadian Patients With Axial Spondyloarthritis: Results From a Multiregistry Analysis (UNISON-Axial SpA)Denis Choquette, Dafna D Gladman, Robert D Inman, et al.
Metabolites|April 21, 2022
Restricting Branched-Chain Amino Acids within a High-Fat Diet Prevents ObesityMing Liu, Yiheng Huang, Hongwei Zhang, et al.
Pageof 26

Showing results (221-230 of 260) with videos related to

Sort By:
Pageof 26
Frontiers in Genetics|April 30, 2019
Integrative Approach to Reveal Cell Type Specificity and Gene Candidates for Psoriatic Arthritis Outside the MHCMatthew T Patrick, Philip E Stuart, Kalpana Raja, et al.
Rheumatology (Oxford, England)|April 6, 2021
Resolution of enthesitis by guselkumab and relationships to disease burden: 1-year results of two phase 3 psoriatic arthritis studiesDennis McGonagle, Iain B McInnes, Atul Deodhar, et al.
Arthritis & Rheumatology (Hoboken, N.J.)|October 12, 2020
Efficacy and Safety of Guselkumab, an Interleukin-23p19-Specific Monoclonal Antibody, Through One Year in Biologic-Naive Patients With Psoriatic ArthritisIain B McInnes, Proton Rahman, Alice B Gottlieb, et al.
Arthritis & Rheumatology (Hoboken, N.J.)|January 22, 2024
Modulation of Interleukin-23 Signaling With Guselkumab in Biologic-Naive Patients Versus Tumor Necrosis Factor Inhibitor-Inadequate Responders With Active Psoriatic ArthritisStefan Siebert, Laura C Coates, Georg Schett, et al.
The Journal of Rheumatology|February 15, 2024
Residual Disease Activity in Canadian Patients With Psoriatic Arthritis Treated With Advanced Therapies: Results From a Multiregistry Analysis (UNISON-PsA)Dafna D Gladman, Vinod Chandran, Cheryl F Rosen, et al.
The Journal of Rheumatology|May 2, 2021
Pooled Safety Results Through 1 Year of 2 Phase III Trials of Guselkumab in Patients With Psoriatic ArthritisProton Rahman, Christopher T Ritchlin, Philip S Helliwell, et al.
The Journal of Rheumatology|September 28, 2007
The Canadian Rheumatology Association/ Spondyloarthritis Research Consortium of Canada treatment recommendations for the management of spondyloarthritis: a national multidisciplinary stakeholder projectWalter P Maksymowych, Dafna Gladman, Proton Rahman, et al.
European Journal of Human Genetics : EJHG|September 4, 2014
Fine mapping of eight psoriasis susceptibility lociSayantan Das, Philip E Stuart, Jun Ding, et al.
The Journal of Rheumatology|July 1, 2025
Residual Disease Activity and Burden of Disease in Canadian Patients With Axial Spondyloarthritis: Results From a Multiregistry Analysis (UNISON-Axial SpA)Denis Choquette, Dafna D Gladman, Robert D Inman, et al.
Metabolites|April 21, 2022
Restricting Branched-Chain Amino Acids within a High-Fat Diet Prevents ObesityMing Liu, Yiheng Huang, Hongwei Zhang, et al.
Pageof 26